Pembrolizumab provided long-term overall survival benefit in second-line treatment and can be effectively used for retreatment after disease progression.
Mutated KRAS protein has been notoriously difficult to target with drugs, but MD Anderson researchers are trying to get at KRAS mRNA using exosomes.
The Angiosarcoma Project uses patient-partnered research to gather information and glean new genomic insights into angiosarcomas.
The trial will assess vopratelimab and Jounce's PD-1 inhibitor in NSCLC patients, and evaluate the ability of an RNA signature to predict response.
The team wants to create NK cell therapies from induced pluripotent stem cells and aims to achieve proof-of-concept for their technology in multiple myeloma.
The aim of the study is to establish a tumor registry based on blood and bone marrow samples from cancer patients with linked outcomes data, which the firm can use for precision drug development.
Increasing understanding of complex tumor biology is reshaping clinical trials in the age of precision medicine, though some view these changes with concern.
Using data from over 500 CAR cell clinical trials, researchers hope to improve patient-trial matching and future immunotherapy designs.
The CVS-Tempus partnership aims to streamline the cancer care process for patients from the point of prescribing onwards and connect patients with local trials.
Researchers at BostonGene and Weill Cornell Medicine hope their approach may provide a more complete and precise characterization of diffuse large B-cell lymphomas.